L-Carnitine Protective Effect in Nephrotoxicity
The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotox
| Condition(s) | Nephrotoxicity |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is: Does L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity? |
| Who can participate | Inclusion Criteria: * Male or female patients. * Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy. * Age between 18 and 75 years. * No serious cardiopulmonary comorbidity which could impair involvement in the study. * Creatinine clearance value above 50 mL/min/1.73 m². * Patients who will scheduled to receive at least 3 cycles of cisplatin. * Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure). Exclusion Criteria: * Pregnancy or lactation. * Metastasis to the central nervous system. * Psychiatric disorders. * Prior treatment with platinum derivatives. * Hypersensitivity to cisplatin, carboplatin or other platinum derivatives. * Patients with active infection or any symptoms of sepsis. * Acute |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Tanta University |
| Locations | Shibīn al Kawm, Egypt |
| Start date | 2025-08-10 |
| NCT ID | NCT07108777 |
| Official listing | https://clinicaltrials.gov/study/NCT07108777 |